Chemelot Ventures

Chemelot Ventures is an active regional venture capital investor in materials and life sciences in the south of The Netherlands. They have a strong focus on value enhancement of their portfolio companies by using their network and the network of their LP's, DSM Nederland, Limburg Province, regional development agency LIOF and Rabobank.

Kim de Boer

Senior Investment Manager

Patrick Claessen

Senior Investment Manager

Marcel Kloosterman

Senior Investment Manager

15 past transactions

Black Bear Carbon

Venture Round in 2018
Carbon black is a form of elemental carbon that is manufactured by the controlled vapour-phase pyrolysis and partial combustion of hydrocarbons. Several processes have been used to produce carbon black, including the oil-furnace, impingement (channel), lampblack, thermal (decomposition of natural gas) and acetylene (decomposition) processes. Carbon blacks are commonly referred to by the process or the source material from which they are made, e.g. furnace black, lampblack, thermal black, acetylene black and channel black. The different grades from the various processes have certain unique characteristics, but it is now possible to produce reasonable approximations of most of these grades using the oil-furnace process, by which more than 95% of the total output of carbon black is produced.

Health Value Creation

Series A in 2017
Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation.

Mito Medical Products

Venture Round in 2017
Mito Medical is developing an innovative diagnostic device that measures vascularity (blood-vessel formation) in the breast and aims to replace the often harmful X-ray cancer screening examination. This technology enables pain-free breast cancer screening with no adverse health risks in both younger and older women, at an earlier stage than is currently the case.

TripleMed

Series A in 2017
TripleMed is developing minimally invasive products against aneurysms, without the need for incisions. The first product fills the aneurysm and prevents blood from entering, whilst leaving a channel for the blood to flow through to reach the other arteries. This enables a better and longer-lasting solution to the problem of aortic aneurysms.

Kriya Materials

Series A in 2017
Kriya Materials is the innovative developer and manufacturer of various metal oxide nano particles as well as their downstream dispersions and functional coating products thereof. Coatings play an important role in our everyday life, although often not recognized by those who do not master the art. Coatings are a big market and many products fall under this category. Kriya Materials focuses itself on the development and manufacturing of various nano metal oxides which it uses internally for the development and production of very high end coatings. The coatings made by Kriya Materials are applied in a wide range of markets, some examples are the Plasma Panel and LCD industry, from Smartphone to touch panels to glass surfaces.

Cristal Therapeutics

Venture Round in 2017
Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec. CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases.

Matisse Pharmaceuticals

Venture Round in 2016
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.

Fortimedix

Series A in 2016
Fortimedix is a global leader in the field of endovascular stents. With full in-house stent development and manufacturing capabilities, they have been a trusted partner for over 15 years. As a leader in stent technology, they invest heavily in research & development which fosters innovation, enables continuous improvement, and fulfils their dedication to operational excellence. At Fortimedix everything they do is inspired by their Mission and Vision. It is of great importance to us that their customers, employees and stakeholders know what they stand for and where they are going.

Materiomics BV

Venture Round in 2015
Materiomics BV is a biotech company located in Enschede, The Netherlands. The company has developed TopoChip. Materiomics BV designs and identifies the best surface for improved functionality and durability of medical and cell culture devices.

Ioniqa Technologies

Venture Round in 2015
Ioniqa Technologies has a patented technology that uses magnetic colloidal systems with nanoparticles to break down PET into a re-usable monomer. The unique feature of this technology is its ability to remove pigmentation which opens up the range of available PET feedstock that can be recycled economically.

Black Bear Carbon

Venture Round in 2015
Carbon black is a form of elemental carbon that is manufactured by the controlled vapour-phase pyrolysis and partial combustion of hydrocarbons. Several processes have been used to produce carbon black, including the oil-furnace, impingement (channel), lampblack, thermal (decomposition of natural gas) and acetylene (decomposition) processes. Carbon blacks are commonly referred to by the process or the source material from which they are made, e.g. furnace black, lampblack, thermal black, acetylene black and channel black. The different grades from the various processes have certain unique characteristics, but it is now possible to produce reasonable approximations of most of these grades using the oil-furnace process, by which more than 95% of the total output of carbon black is produced.

Cristal Therapeutics

Venture Round in 2014
Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec. CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases.

Quality Circular Polymers

Funding Round in 2014
QCP provides brand owners and plastics convertors with polymers of high and consistent quality based on used plastics.

Enzypep

Funding Round in 2014
Enzypep designs and develops oligopeptides for pharmaceutical products. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner. It began operation in 2012, with its headquarters in Geleen in the Netherlands.

Chemtrix

Venture Round in 2008
Chemtrix BV supplies complete and customized microreactor systems for R&D and commercial manufacturing. Chemtrix’ microreactors enhance process efficiency, energy efficiency and safety of chemical synthesis in the fine chemical and pharmaceutical industries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.